Antipsychotic Use Doesn't Up Congenital Malformations

This article originally appeared here.
Share this content:
Antipsychotic Use Doesn't Up Congenital Malformations
Antipsychotic Use Doesn't Up Congenital Malformations

WEDNESDAY, Aug. 17, 2016 (HealthDay News) -- Use of antipsychotics (APs) in pregnancy does not appear to increase the risk for congenital malformations, according to a study published online Aug. 17 in JAMA Psychiatry.

Krista F. Huybrechts, Ph.D., from Brigham and Women's Hospital in Boston, and colleagues examined the risk for congenital malformations and cardiac malformations associated with exposure to APs in the first trimester in a sample of 1,341,715 pregnancies.

The researchers found that 0.69 and 0.05 percent of women filled at least one prescription for an atypical AP and filled at least one prescription for a typical AP during the first trimester, respectively. Congenital malformations were diagnosed in 32.7 per 1,000 births not exposed to APs, compared with 44.5 and 38.2 per 1,000 births exposed to atypical and typical APs, respectively. For atypical APs there was an increased risk for malformations in unadjusted analyses (relative risk [RR], 1.36; 95 percent confidence interval [CI], 1.24 to 1.50), but not for typical APs (RR, 1.17; 95 percent CI, 0.81 to 1.68). After adjustment for confounding variables, the RRs were reduced for atypical APs (1.05; 95 percent CI, 0.96 to 1.16) and for typical APs (0.90; 95 percent CI, 0.62 to 1.31). Similar findings were seen for cardiac malformations.

"Evidence from this large study suggests that use of APs early in pregnancy generally does not meaningfully increase the risk for congenital malformations overall or cardiac malformations in particular," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Price Transparency Intervention Doesn't Cut Lab Test Orders

Price Transparency Intervention Doesn't Cut Lab Test Orders

No significant changes in overall test-ordering behavior or associated fees in adjusted analyses

More Risks on School Playgrounds Linked to Happier Children

More Risks on School Playgrounds Linked to Happier ...

Greater opportunities for risk, challenge associated with fewer reports of bullying to adults

Black Men Have Higher Rate of Preclinical Prostate Cancer

Black Men Have Higher Rate of Preclinical Prostate ...

Also increased risk of progression to metastatic disease compared with the general population

is free, fast, and customized just for you!

Already a member?

Sign In Now »